[Cytostatic therapy causing the loss of serological activity in thrombocytes].
D000017:ABO Blood-Group System; D000042:Absorption; D000230:Adenocarcinoma / Q000188:drug therapy / Q000276:immunology; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001792:Blood Platelets / Q000187:drug effects / Q000276:immunology*; D001943:Breast Neoplasms / Q000188:drug therapy / Q000276:immunology; D002822:Choriocarcinoma / Q000188:drug therapy / Q000276:immunology; D003520:Cyclophosphamide / Q000009:adverse effects; D003609:Dactinomycin / Q000009:adverse effects; D004407:Dysgerminoma / Q000188:drug therapy / Q000276:immunology; D004912:Erythrocytes / Q000276:immunology; D005260:Female; D006386:Hemagglutination Tests; D006801:Humans; D007106:Immune Sera; D007519:Isoantigens / Q000032:analysis*; D007938:Leukemia / Q000188:drug therapy / Q000276:immunology; D007962:Leukocytes / Q000276:immunology; D008297:Male; D015122:Mercaptopurine / Q000009:adverse effects; D008727:Methotrexate / Q000009:adverse effects; D009588:Nitrogen Mustard Compounds / Q000009:adverse effects; D011247:Pregnancy; D014499:Uracil Mustard / Q000009:adverse effects
D000017:ABO Blood-Group System; D000970:Antineoplastic Agents; D007106:Immune Sera; D007519:Isoantigens; D009588:Nitrogen Mustard Compounds; D003609:Dactinomycin; D003520:Cyclophosphamide; D015122:Mercaptopurine; D014499:Uracil Mustard; D008727:Methotrexate
Zytostatische Behandlung als Ursache des Verlustes der serologischen Aktivität der Thrombozyten.